Equasens SA
PAR:EQS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44.85
66.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one EQS stock under the Base Case scenario is 72.17 EUR. Compared to the current market price of 44.85 EUR, Equasens SA is Undervalued by 38%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Equasens SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for EQS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Equasens SA
Balance Sheet Decomposition
Equasens SA
Current Assets | 132.3m |
Cash & Short-Term Investments | 54.7m |
Receivables | 67.3m |
Other Current Assets | 10.3m |
Non-Current Assets | 261.8m |
Long-Term Investments | 95.1m |
PP&E | 32.9m |
Intangibles | 130.3m |
Other Non-Current Assets | 3.5m |
Current Liabilities | 108.1m |
Accounts Payable | 16.1m |
Other Current Liabilities | 92m |
Non-Current Liabilities | 66.6m |
Long-Term Debt | 44.7m |
Other Non-Current Liabilities | 22m |
Earnings Waterfall
Equasens SA
Revenue
|
219.8m
EUR
|
Cost of Revenue
|
-69.1m
EUR
|
Gross Profit
|
150.6m
EUR
|
Operating Expenses
|
-95.4m
EUR
|
Operating Income
|
55.2m
EUR
|
Other Expenses
|
-8.2m
EUR
|
Net Income
|
47m
EUR
|
Free Cash Flow Analysis
Equasens SA
EUR | |
Free Cash Flow | EUR |
EQS Profitability Score
Profitability Due Diligence
Equasens SA's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
Score
Equasens SA's profitability score is 66/100. The higher the profitability score, the more profitable the company is.
EQS Solvency Score
Solvency Due Diligence
Equasens SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
Equasens SA's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EQS Price Targets Summary
Equasens SA
According to Wall Street analysts, the average 1-year price target for EQS is 85.1 EUR with a low forecast of 64.94 EUR and a high forecast of 110.25 EUR.
Dividends
Current shareholder yield for EQS is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Equasens engages in the development of management software packages for drugstores. The company is headquartered in Villers-Les-Nancy, Grand Est. The company went IPO on 2000-10-20. The firm is engaged in the development and integration of management software packages for drugstores. The company offers all IT (Information Technology) and High-Tech fields related to Health and in specialized fields which are associated to it such as IT for pharmacies, solutions for e-Health, solutions for pharmaceutical industry, solutions for patients etc. The firm operates in four divisions that includes Europe Pharmacy Solutions Division including France Pharmacy Section and Belgium and Luxembourg Pharmacy Section, Solutions for sanitary and medico-social entities Division, e-Health Solutions Division including e-Laboratories section, e-Patients section and e-Connect section and Fintech Division.
Contact
IPO
Employees
Officers
The intrinsic value of one EQS stock under the Base Case scenario is 72.17 EUR.
Compared to the current market price of 44.85 EUR, Equasens SA is Undervalued by 38%.